TSX VENTURE EXCHANGE: AVI
QUEBEC, June 14 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) today announced the signature of a
definitive agreement with Diversified Natural Products Inc. ("DNP") and Thorne
Research Inc. ("Thorne") to distribute Dermylex(TM) to Dermatology Clinics,
Health Practitioners and Health Food stores in the U.S. market.
The agreement is exclusive for an initial period of five (5) years, with
certain objectives to be attained.
"The U.S. market is our top priority for 2007 and this agreement
validates Advitech's determination to penetrate the U.S. market as early as
the 3rd quarter of 2007. We are proud to have achieved this milestone"
commented Mr. Renaud Beauchesne, President and Chief Executive Officer of
Advitech. "DNP and Thorne are two leaders in their respective field of
expertise and will allow Dermylex(TM) to gain rapid sales growth. This
approach in two separate distribution networks with Thorne and DNP will allow
Dermylex(TM), a product with validated clinical studies and strong science, to
be professionally referred for psoriasis patients, through dermatology clinics
and by Health Practitioners while, also being available in specialized Health
Food Stores across the United States. We are proud to partner with DNP and
Thorne for Dermylex(TM) distribution on the U.S. market and we should be able
to build a stronger strategic alliance for the future by adding-up new
opportunities generated by our current product pipeline" added Mr. Renaud
"Our growth strategy is based on offering natural products possessing
clinical evidence and patent protection, for chronic conditions such as
psoriasis. We are happy to add Dermylex(TM) to our product line and establish
a marketing and scientific partnership with Advitech" commented Mr. Paul
Jacobson, President and Chief Executive Officer of DNP.
DNP is a New York based company that markets specialty ingredients that
are patent protected and have clinically proven efficacy. Adding Dermylex(TM)
to its product line will both increase DNP's offering and provide Dermylex(TM)
with ready access to the U.S. market.
According to a survey conducted by ConsumerLab earlier this year, Thorne
is the leader in the U.S. Health Practitioners market segment. Thorne will
leverage this strength to promote and distribute Dermylex(TM) in the Health
Practitioner channel. Thorne will also target U.S. Health Food Stores through
its Sound Nutrition division.
About Thorne Research Inc. http://www.thorne.com/
For over 20 years, Thorne has set the standard for exceptional
formulations, quality, and purity in the nutritional supplement industry. The
leader in the practitioner channel, according to Consumer Labs' 2007 survey,
Thorne's philosophy is to provide the purest supplements humanly possible at a
reasonable price. Over the years, the business has changed dramatically, but
the Thorne philosophy has stayed the same - manufacture the finest, purest,
highest quality nutritional supplements in the world.
About Diversified Natural products Inc. http://www.dnpworld.com/
DNP is a bio-based technology company. They are in the business of
developing natural and green products for manufacturers and for everyday
living. DNP's products are derived from renewable resources. For their
customers, they develop effective, useful products that are healthy, safe and
environmentally friendly. In addition to its natural health division, which
develops and commercializes patent protected natural ingredients for chronic
conditions, DNP has a biobased organic acids division, which produces products
such as succinct acid that can be used as substitutes to petroleum based
chemicals in the plastic and solvent markets.
About Advitech Inc. www.advitech.com
Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
Immune-Mediated Inflammatory Disorders (IMID), such as psoriasis and
inflammatory bowel disease.
Dermylex(TM) developed by Advitech, is an oral natural health product
relieving mild-to-moderate psoriasis symptoms. Two clinical trials, one of
them multi-center, double-blind and placebo-controlled, for 112 days and on
84 patients, clinically proved the efficacy and safety of Dermylex(TM) for
that type of psoriasis. Dermylex(TM) is currently available in Canada. For
more information, please visit the www.dermylex.ca website.
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The TSX Venture Exchange does not
accept responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Renaud Beauchesne, MBA, President and Chief
Executive Officer, Advitech Inc., (418) 686-7498, ext. 228, email@example.com;
www.advitech.com; Serge Comeau, Investor's relations, Advitech Inc., (514)